Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
645.01B
Market cap645.01B
Price-Earnings ratio
31.52
Price-Earnings ratio31.52
Dividend yield
1.94%
Dividend yield1.94%
Average volume
6.76M
Average volume6.76M
High today
$272.02
High today$272.02
Low today
$265.59
Low today$265.59
Open price
$268.63
Open price$268.63
Volume
5.62M
Volume5.62M
52 Week high
$281.07
52 Week high$281.07
52 Week low
$179.80
52 Week low$179.80

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $267.63, with a market capitalization of 645.01B. The stock trades at a price-to-earnings (P/E) ratio of 31.52 and offers a dividend yield of 1.94%.

During the trading session on 2026-09-29, Johnson & Johnson(JNJ) shares reached a daily high of $272.02 and a low of $265.59. At a current price of $267.63, the stock is +0.8% higher than the low and still -1.6% under the high.

Trading volume for Johnson & Johnson(JNJ) stock has reached 5.62M, versus its average volume of 6.76M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $179.80.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $281.07 and a low of $179.80.

JNJ News

Zacks 3h
Johnson & Johnson Sees a More Significant Dip Than Broader Market: Some Facts to Know

Johnson & Johnson (JNJ Quick QuoteJNJ - Free Report) closed at $267.66 in the latest trading session, marking a -1.58% move from the prior day. The stock'...

Johnson & Johnson Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks 5h
Defensive Dividends: 3 Companies Investors Can Rely On

When seeking reliable dividend payouts, look no further than the Dividend Kings. Several members of the elite club, including Johnson & Johnson (JNJ Quick Quote...

Defensive Dividends: 3 Companies Investors Can Rely On
CNBC 7h
Tech leaders arrive at White House for AI luncheon with Trump - CNBC

...

Tech leaders arrive at White House for AI luncheon with Trump - CNBC

Analyst ratings

70%

of 27 ratings
Buy
70.4%
Hold
22.2%
Sell
7.4%

More JNJ News

Benzinga 7h
Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss

Johnson & Johnson (NYSE:JNJ) is scheduled to report its third-quarter fiscal 2027 results on Nov. 12. Bank of America Securities analyst Jason Gerberry expects...

Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss
Nasdaq 11h
J&J's IMAAVY Shows Sustained Disease Control In New GMG Data

(RTTNews) - Tuesday, Johnson & Johnson (JNJ) said new data from the Phase 2/3 long-term extension study showed sustained disease control through two years, alon...

J&J's IMAAVY Shows Sustained Disease Control In New GMG Data
TipRanks 11h
Johnson & Johnson’s Imaavy shows efficacy in gMG Phase 2/3 trial

Johnson & Johnson announced new findings on Imaavy – nipocalimab-aahu – for the treatment of generalized myasthenia gravis, or gMG, across 15 novel abstracts to...

24/7 Wall St. 12h
Living Off Dividends at 65: 3 Stocks That Raised Payouts for Longer Than 30 Years

Investing Living Off Dividends at 65: 3 Stocks That Raised Payouts for Longer Than 30 Years Three stocks have raised their dividends for over 30 consecutive yea...

Living Off Dividends at 65: 3 Stocks That Raised Payouts for Longer Than 30 Years
TipRanks 13h
Johnson & Johnson price target raised to $285 from $270 at JPMorgan

JPMorgan raised the firm’s price target on Johnson & Johnson to $285 from $270 and keeps a Neutral rating on the shares ahead of the earnings report on October...

24/7 Wall St. 1d
Johnson & Johnson's Next Growth Engine Is Taking Shape

Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and mounting litigation costs threaten t...

Johnson & Johnson's Next Growth Engine Is Taking Shape
Simply Wall St 3d
How New TREMFYA Data At Johnson & Johnson Stock Has Changed Its Investment Story

Johnson & Johnson reported past clinical milestones for TREMFYA in axial psoriatic arthritis and long-term CARTITUDE-2 data for CARVYKTI in early line multiple...

How New TREMFYA Data At Johnson & Johnson Stock Has Changed Its Investment Story

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.